Open

Early Stage Lung Cancer trial

This is a study for people with early-stage inoperable lung cancer. We want to find out if adding a drug called atezolizumab to stereotactic body radiation therapy (SBRT) is more effective than SBRT alone for this type of cancer.

Age & Gender

18 years ~ 99 years
Male, Female

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

If you decide to take part, you will have a physical exam and some labs drawn. You will receive a type of radiation called SBRT. You may or may not receive a total of 8 doses of an infusion called atezolizumab, once every 3 weeks. You will follow-up with our office every 6 months for 5 years.

In-person visits:
15-30

Total length of participation:
5 years

Looking for Specific Volunteers

Able to participate:

You have early stage lung cancer
You did not receive surgery for your lung cancer
Willing to undergo a CT scan
Willing to have pulmonary function testing

Not eligible if:

No current heart conditions
You do not have an autoimmune disease
You are not pregnant

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Becky Clinard
CancCtrOncologyClinicalResearch@unchealth.unc.edu
(919) 784-2500

Primary Visit Location

UNC Rex Cancer Center
2901 Blue Ridge Rd, Raleigh, NC 27607, USA

Additional Study Information

Principal Investigator

Ranjit Joseph
UNC Hospitals - Rex

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lung)

IRB Number

22-3377

ClinicalTrials.gov

NCT04214262

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.